NEW YORK (GenomeWeb News) - VIA Pharmaceuticals said today that it has secured funding from Genome Quebec to perform a pharmacogenomics sub-study as part of clinical trials for its lead candidate for acute coronary syndrome.
 
VIA said it will collaborate with the Montreal Heart Institute to perform genomics and proteomics studies and develop a genotyping panel it could use in Phase II clinical trials for its ACS drug VIA-2291.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.